Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pleural Neoplasms | 21 | 2021 | 584 | 1.900 |
Why?
|
Mesothelioma | 21 | 2021 | 774 | 1.650 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 49 | 2024 | 5388 | 1.580 |
Why?
|
Lung Neoplasms | 66 | 2025 | 13483 | 1.530 |
Why?
|
Medulloblastoma | 10 | 2022 | 657 | 0.970 |
Why?
|
Cerebellar Neoplasms | 9 | 2022 | 570 | 0.900 |
Why?
|
Photons | 9 | 2020 | 571 | 0.860 |
Why?
|
Brain Neoplasms | 18 | 2024 | 9064 | 0.650 |
Why?
|
Protein Kinase Inhibitors | 26 | 2024 | 5695 | 0.610 |
Why?
|
Adenocarcinoma | 19 | 2022 | 6361 | 0.560 |
Why?
|
Quinazolines | 17 | 2012 | 1366 | 0.560 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2025 | 9378 | 0.490 |
Why?
|
Drug Resistance, Neoplasm | 17 | 2024 | 5334 | 0.450 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 31 | 2025 | 11859 | 0.450 |
Why?
|
Pneumonectomy | 8 | 2021 | 1147 | 0.410 |
Why?
|
Propensity Score | 1 | 2020 | 1973 | 0.400 |
Why?
|
Receptor Protein-Tyrosine Kinases | 10 | 2019 | 1621 | 0.390 |
Why?
|
Neoplasm Staging | 33 | 2021 | 11202 | 0.370 |
Why?
|
Aminopyridines | 4 | 2022 | 576 | 0.360 |
Why?
|
Ependymoma | 5 | 2021 | 310 | 0.360 |
Why?
|
Protons | 9 | 2024 | 1073 | 0.340 |
Why?
|
Antineoplastic Agents | 25 | 2018 | 13635 | 0.340 |
Why?
|
Pancreatic Neoplasms | 8 | 2022 | 5454 | 0.340 |
Why?
|
Radiotherapy Dosage | 16 | 2024 | 2863 | 0.340 |
Why?
|
Relative Biological Effectiveness | 8 | 2020 | 299 | 0.330 |
Why?
|
Mutation | 35 | 2024 | 30210 | 0.310 |
Why?
|
Neoadjuvant Therapy | 9 | 2021 | 2897 | 0.300 |
Why?
|
Pyrazoles | 7 | 2022 | 2031 | 0.300 |
Why?
|
Radiotherapy, Conformal | 6 | 2018 | 533 | 0.290 |
Why?
|
Radiodermatitis | 3 | 2019 | 58 | 0.290 |
Why?
|
Prognosis | 37 | 2021 | 29905 | 0.290 |
Why?
|
Fluorouracil | 6 | 2021 | 1648 | 0.280 |
Why?
|
Central Nervous System Neoplasms | 5 | 2020 | 918 | 0.280 |
Why?
|
Glioma | 4 | 2019 | 3492 | 0.280 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2025 | 453 | 0.280 |
Why?
|
Aged, 80 and over | 61 | 2025 | 59497 | 0.270 |
Why?
|
Middle Aged | 115 | 2025 | 223035 | 0.270 |
Why?
|
Carbazoles | 2 | 2018 | 229 | 0.270 |
Why?
|
Radiation Injuries | 4 | 2019 | 1181 | 0.270 |
Why?
|
Cranial Irradiation | 3 | 2022 | 384 | 0.270 |
Why?
|
Gene Amplification | 5 | 2020 | 1088 | 0.270 |
Why?
|
Humans | 192 | 2025 | 766019 | 0.260 |
Why?
|
Lactams, Macrocyclic | 3 | 2022 | 318 | 0.260 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2021 | 1609 | 0.260 |
Why?
|
Lactams | 3 | 2022 | 159 | 0.260 |
Why?
|
Cholangiocarcinoma | 3 | 2018 | 577 | 0.260 |
Why?
|
Aged | 99 | 2025 | 171170 | 0.250 |
Why?
|
Male | 134 | 2025 | 363880 | 0.250 |
Why?
|
Carboplatin | 4 | 2021 | 787 | 0.250 |
Why?
|
Female | 140 | 2025 | 396174 | 0.250 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2010 | 316 | 0.250 |
Why?
|
Radiosurgery | 3 | 2022 | 1328 | 0.250 |
Why?
|
Cisplatin | 9 | 2013 | 1654 | 0.250 |
Why?
|
Carcinoma, Hepatocellular | 5 | 2020 | 2328 | 0.240 |
Why?
|
Liver Neoplasms | 6 | 2020 | 4354 | 0.240 |
Why?
|
Adult | 100 | 2025 | 223110 | 0.240 |
Why?
|
Kaplan-Meier Estimate | 18 | 2020 | 6506 | 0.240 |
Why?
|
Transplantation Conditioning | 6 | 2014 | 1635 | 0.220 |
Why?
|
Radiotherapy, Adjuvant | 9 | 2022 | 1777 | 0.220 |
Why?
|
Proto-Oncogene Proteins | 7 | 2021 | 4520 | 0.220 |
Why?
|
Survival Rate | 29 | 2020 | 12822 | 0.220 |
Why?
|
Brain Stem | 3 | 2022 | 852 | 0.220 |
Why?
|
Radium | 1 | 2024 | 70 | 0.210 |
Why?
|
Lymphoma, Non-Hodgkin | 8 | 2013 | 1374 | 0.210 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 562 | 0.210 |
Why?
|
Bone Marrow Transplantation | 8 | 2011 | 2729 | 0.200 |
Why?
|
Fibromatosis, Aggressive | 2 | 2013 | 125 | 0.190 |
Why?
|
Treatment Outcome | 39 | 2025 | 65203 | 0.190 |
Why?
|
Retrospective Studies | 44 | 2022 | 81544 | 0.190 |
Why?
|
Olfaction Disorders | 1 | 2024 | 224 | 0.190 |
Why?
|
Sarcoma | 4 | 2014 | 1801 | 0.190 |
Why?
|
Disease-Free Survival | 13 | 2017 | 6840 | 0.190 |
Why?
|
Radiotherapy | 5 | 2021 | 1491 | 0.190 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 249 | 0.190 |
Why?
|
Retinoblastoma | 2 | 2014 | 316 | 0.190 |
Why?
|
Hypopituitarism | 1 | 2023 | 253 | 0.180 |
Why?
|
Cognition | 2 | 2018 | 7050 | 0.180 |
Why?
|
Combined Modality Therapy | 19 | 2022 | 8524 | 0.180 |
Why?
|
ras Proteins | 5 | 2014 | 1054 | 0.180 |
Why?
|
Prospective Studies | 22 | 2024 | 54804 | 0.180 |
Why?
|
Gene Rearrangement | 4 | 2018 | 1142 | 0.180 |
Why?
|
Piperidines | 3 | 2018 | 1664 | 0.180 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2021 | 1762 | 0.180 |
Why?
|
Survival Analysis | 20 | 2019 | 10089 | 0.180 |
Why?
|
Physicians, Women | 2 | 2024 | 516 | 0.170 |
Why?
|
Pyridines | 5 | 2020 | 2889 | 0.170 |
Why?
|
Young Adult | 33 | 2024 | 59858 | 0.170 |
Why?
|
Graft vs Leukemia Effect | 2 | 2011 | 122 | 0.170 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2021 | 2425 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2015 | 3546 | 0.160 |
Why?
|
Phospholipase D | 1 | 2019 | 71 | 0.160 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2020 | 135 | 0.160 |
Why?
|
Infratentorial Neoplasms | 2 | 2017 | 94 | 0.160 |
Why?
|
Pituitary Neoplasms | 2 | 2023 | 1322 | 0.160 |
Why?
|
Central Nervous System | 2 | 2025 | 1343 | 0.160 |
Why?
|
Follow-Up Studies | 27 | 2022 | 39233 | 0.160 |
Why?
|
Bile Duct Neoplasms | 2 | 2015 | 624 | 0.160 |
Why?
|
Congresses as Topic | 1 | 2024 | 811 | 0.160 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2022 | 781 | 0.160 |
Why?
|
Nonlinear Dynamics | 1 | 2001 | 490 | 0.150 |
Why?
|
Molecular Targeted Therapy | 5 | 2023 | 2825 | 0.150 |
Why?
|
Lymphopenia | 1 | 2021 | 298 | 0.150 |
Why?
|
Neuroma, Acoustic | 1 | 2022 | 456 | 0.150 |
Why?
|
Bilirubin | 1 | 2020 | 439 | 0.150 |
Why?
|
Platinum | 1 | 2019 | 219 | 0.150 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2012 | 328 | 0.150 |
Why?
|
Radiation Oncology | 1 | 2024 | 568 | 0.150 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2021 | 347 | 0.140 |
Why?
|
Neurosecretory Systems | 1 | 2019 | 223 | 0.140 |
Why?
|
Breast Neoplasms | 7 | 2021 | 21072 | 0.140 |
Why?
|
Deoxycytidine | 2 | 2014 | 886 | 0.140 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2014 | 5752 | 0.140 |
Why?
|
Biometry | 1 | 2001 | 571 | 0.140 |
Why?
|
Wechsler Scales | 1 | 2018 | 255 | 0.140 |
Why?
|
Losartan | 1 | 2019 | 263 | 0.140 |
Why?
|
Gene Expression Profiling | 6 | 2016 | 9525 | 0.140 |
Why?
|
Intraoperative Care | 2 | 2013 | 768 | 0.140 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2020 | 455 | 0.140 |
Why?
|
Graft vs Host Disease | 6 | 2014 | 3079 | 0.140 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2018 | 2054 | 0.140 |
Why?
|
Organophosphorus Compounds | 1 | 2018 | 209 | 0.140 |
Why?
|
Serum Albumin | 1 | 2020 | 674 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 252 | 0.130 |
Why?
|
Hematologic Diseases | 1 | 2020 | 500 | 0.130 |
Why?
|
DNA Mutational Analysis | 7 | 2020 | 4112 | 0.130 |
Why?
|
Societies, Medical | 3 | 2024 | 3955 | 0.130 |
Why?
|
Piperazines | 2 | 2025 | 2547 | 0.130 |
Why?
|
In Situ Hybridization, Fluorescence | 9 | 2013 | 2510 | 0.130 |
Why?
|
Child, Preschool | 22 | 2024 | 42509 | 0.130 |
Why?
|
Hyperthermia, Induced | 2 | 2013 | 414 | 0.130 |
Why?
|
Inhibitor of Apoptosis Proteins | 2 | 2007 | 200 | 0.130 |
Why?
|
Immunity, Humoral | 2 | 2010 | 608 | 0.130 |
Why?
|
Pulmonary Fibrosis | 2 | 2018 | 503 | 0.120 |
Why?
|
Meningeal Neoplasms | 2 | 2017 | 1252 | 0.120 |
Why?
|
Anus Neoplasms | 1 | 2019 | 336 | 0.120 |
Why?
|
Adolescent | 32 | 2024 | 88808 | 0.120 |
Why?
|
Spinal Neoplasms | 2 | 2014 | 708 | 0.120 |
Why?
|
Histocompatibility | 2 | 2009 | 327 | 0.120 |
Why?
|
Rhabdoid Tumor | 2 | 2017 | 209 | 0.120 |
Why?
|
Dihydrotestosterone | 1 | 2015 | 194 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 586 | 0.120 |
Why?
|
Hearing Loss | 1 | 2022 | 785 | 0.120 |
Why?
|
Cell Line, Tumor | 16 | 2021 | 17071 | 0.120 |
Why?
|
Soft Tissue Neoplasms | 2 | 2014 | 1163 | 0.120 |
Why?
|
Time Factors | 23 | 2021 | 40100 | 0.120 |
Why?
|
Pyrimidines | 2 | 2018 | 3050 | 0.110 |
Why?
|
T-Lymphocytes | 6 | 2018 | 10260 | 0.110 |
Why?
|
Teratoma | 2 | 2017 | 402 | 0.110 |
Why?
|
Urate Oxidase | 1 | 2014 | 33 | 0.110 |
Why?
|
Guanine | 2 | 2012 | 281 | 0.110 |
Why?
|
Glutamates | 2 | 2012 | 384 | 0.110 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 215 | 0.110 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2020 | 921 | 0.100 |
Why?
|
Fibromatosis, Abdominal | 1 | 2012 | 21 | 0.100 |
Why?
|
Myxosarcoma | 1 | 2012 | 11 | 0.100 |
Why?
|
Multivariate Analysis | 5 | 2020 | 12061 | 0.100 |
Why?
|
Child | 23 | 2024 | 80567 | 0.100 |
Why?
|
Anticonvulsants | 1 | 2022 | 1920 | 0.100 |
Why?
|
Retinal Neoplasms | 1 | 2014 | 146 | 0.100 |
Why?
|
Gene Expression | 5 | 2014 | 7581 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 715 | 0.100 |
Why?
|
Genotype | 11 | 2017 | 13027 | 0.100 |
Why?
|
Registries | 4 | 2019 | 8343 | 0.100 |
Why?
|
Sulfones | 1 | 2015 | 447 | 0.100 |
Why?
|
Carcinoma, Large Cell | 1 | 2012 | 114 | 0.100 |
Why?
|
Lymphoma | 3 | 2018 | 1897 | 0.100 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2012 | 64 | 0.100 |
Why?
|
Neoplasm Proteins | 5 | 2009 | 3594 | 0.100 |
Why?
|
Asbestos | 1 | 2013 | 250 | 0.100 |
Why?
|
Tissue Fixation | 2 | 2016 | 245 | 0.100 |
Why?
|
Interferon-gamma | 2 | 2011 | 3159 | 0.100 |
Why?
|
Lymphocyte Transfusion | 1 | 2012 | 236 | 0.090 |
Why?
|
Leucovorin | 6 | 2021 | 643 | 0.090 |
Why?
|
Carcinogens | 1 | 2013 | 452 | 0.090 |
Why?
|
Chimera | 1 | 2012 | 455 | 0.090 |
Why?
|
Quality of Life | 7 | 2023 | 13464 | 0.090 |
Why?
|
Esophagectomy | 1 | 2015 | 478 | 0.090 |
Why?
|
Esophageal Neoplasms | 2 | 2015 | 1659 | 0.090 |
Why?
|
Hematologic Neoplasms | 3 | 2014 | 1926 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 6 | 2018 | 1765 | 0.090 |
Why?
|
Chordoma | 1 | 2014 | 343 | 0.090 |
Why?
|
Treatment Failure | 7 | 2017 | 2653 | 0.090 |
Why?
|
Extremities | 2 | 2014 | 868 | 0.090 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 4047 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2011 | 633 | 0.090 |
Why?
|
Fibrosarcoma | 1 | 2012 | 312 | 0.090 |
Why?
|
Neoplasms | 7 | 2021 | 22336 | 0.090 |
Why?
|
Chimerism | 1 | 2011 | 154 | 0.090 |
Why?
|
Translocation, Genetic | 1 | 2016 | 1392 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 1 | 2020 | 2793 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 646 | 0.090 |
Why?
|
Data Collection | 1 | 2019 | 3318 | 0.090 |
Why?
|
Hematopoietic Stem Cell Mobilization | 2 | 2011 | 227 | 0.090 |
Why?
|
Disease Progression | 10 | 2021 | 13614 | 0.090 |
Why?
|
Genes, erbB-1 | 1 | 2010 | 161 | 0.080 |
Why?
|
Neutropenia | 3 | 2011 | 894 | 0.080 |
Why?
|
Histocompatibility Testing | 2 | 2009 | 726 | 0.080 |
Why?
|
Swine Diseases | 1 | 2009 | 61 | 0.080 |
Why?
|
Phthalazines | 2 | 2025 | 397 | 0.080 |
Why?
|
Thoracic Surgical Procedures | 1 | 2013 | 348 | 0.080 |
Why?
|
Immunohistochemistry | 9 | 2020 | 11035 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 540 | 0.080 |
Why?
|
Spinal Cord | 2 | 2015 | 1811 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 2 | 2014 | 1131 | 0.080 |
Why?
|
Umbilical Cord | 1 | 2010 | 178 | 0.080 |
Why?
|
Lymph Nodes | 2 | 2019 | 3457 | 0.080 |
Why?
|
Body Height | 1 | 2015 | 1561 | 0.080 |
Why?
|
B-Lymphocytes | 4 | 2011 | 4783 | 0.080 |
Why?
|
Tumor Burden | 4 | 2018 | 1889 | 0.080 |
Why?
|
Receptors, Growth Factor | 1 | 2010 | 324 | 0.080 |
Why?
|
Breast | 1 | 2018 | 1950 | 0.080 |
Why?
|
SOXB1 Transcription Factors | 1 | 2010 | 283 | 0.080 |
Why?
|
Immunotherapy | 3 | 2021 | 4746 | 0.080 |
Why?
|
Cell Transplantation | 1 | 2010 | 473 | 0.080 |
Why?
|
Meningioma | 1 | 2017 | 1221 | 0.080 |
Why?
|
Neoplasms, Second Primary | 2 | 2013 | 1056 | 0.080 |
Why?
|
Hodgkin Disease | 2 | 2013 | 1383 | 0.080 |
Why?
|
Lung Diseases | 3 | 2007 | 1941 | 0.080 |
Why?
|
Risk Factors | 14 | 2021 | 74837 | 0.080 |
Why?
|
Feasibility Studies | 6 | 2019 | 5301 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2020 | 8613 | 0.080 |
Why?
|
beta Catenin | 1 | 2013 | 1047 | 0.070 |
Why?
|
Estradiol | 1 | 2015 | 1947 | 0.070 |
Why?
|
Rhabdomyosarcoma | 1 | 2011 | 354 | 0.070 |
Why?
|
Lung | 3 | 2018 | 10061 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 4565 | 0.070 |
Why?
|
Transplantation Chimera | 2 | 2007 | 609 | 0.070 |
Why?
|
Survivors | 3 | 2018 | 2375 | 0.070 |
Why?
|
Genes, ras | 4 | 2014 | 656 | 0.070 |
Why?
|
Alleles | 3 | 2021 | 6892 | 0.070 |
Why?
|
Infant | 11 | 2021 | 36424 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1653 | 0.070 |
Why?
|
Spine | 1 | 2014 | 1132 | 0.070 |
Why?
|
Drug Administration Schedule | 7 | 2015 | 4853 | 0.070 |
Why?
|
Pulmonary Surgical Procedures | 1 | 2007 | 33 | 0.070 |
Why?
|
Frozen Sections | 1 | 2007 | 152 | 0.070 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2007 | 105 | 0.070 |
Why?
|
Proportional Hazards Models | 8 | 2019 | 12529 | 0.070 |
Why?
|
Apoptosis | 6 | 2019 | 9507 | 0.070 |
Why?
|
Polymorphism, Genetic | 2 | 2007 | 4248 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2019 | 3605 | 0.070 |
Why?
|
DNA, Neoplasm | 2 | 2009 | 1739 | 0.070 |
Why?
|
Craniopharyngioma | 1 | 2009 | 276 | 0.060 |
Why?
|
Ovarian Neoplasms | 3 | 1998 | 4904 | 0.060 |
Why?
|
Vincristine | 7 | 2020 | 1037 | 0.060 |
Why?
|
Organs at Risk | 2 | 2022 | 352 | 0.060 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 658 | 0.060 |
Why?
|
Amino Acid Substitution | 2 | 2021 | 1742 | 0.060 |
Why?
|
Total Quality Management | 1 | 2007 | 264 | 0.060 |
Why?
|
Models, Statistical | 1 | 2020 | 5088 | 0.060 |
Why?
|
Fundoplication | 1 | 2006 | 146 | 0.060 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 685 | 0.060 |
Why?
|
Jehovah's Witnesses | 1 | 2004 | 13 | 0.060 |
Why?
|
Body Weight | 1 | 2015 | 4626 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2012 | 2878 | 0.060 |
Why?
|
Down-Regulation | 1 | 2012 | 2927 | 0.060 |
Why?
|
Testosterone | 1 | 2015 | 2495 | 0.060 |
Why?
|
Pleura | 1 | 2006 | 243 | 0.060 |
Why?
|
Immunity, Cellular | 1 | 2010 | 1557 | 0.060 |
Why?
|
Lymphoma, B-Cell | 1 | 1991 | 943 | 0.060 |
Why?
|
Smoking | 2 | 2012 | 9077 | 0.060 |
Why?
|
Whole-Body Irradiation | 3 | 2009 | 438 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7558 | 0.060 |
Why?
|
Morpholines | 1 | 2007 | 584 | 0.060 |
Why?
|
Fever | 1 | 2011 | 1607 | 0.060 |
Why?
|
Genes, Tumor Suppressor | 1 | 2008 | 1058 | 0.060 |
Why?
|
Algorithms | 2 | 2021 | 14065 | 0.060 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2022 | 1642 | 0.050 |
Why?
|
Cysts | 1 | 2009 | 685 | 0.050 |
Why?
|
Radiography | 5 | 2015 | 6943 | 0.050 |
Why?
|
Leukemia | 1 | 2011 | 1521 | 0.050 |
Why?
|
Boronic Acids | 1 | 2007 | 915 | 0.050 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 266 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2008 | 2342 | 0.050 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2006 | 281 | 0.050 |
Why?
|
Paraffin Embedding | 2 | 2016 | 302 | 0.050 |
Why?
|
Cyclophosphamide | 10 | 2008 | 2232 | 0.050 |
Why?
|
Skin Neoplasms | 2 | 2012 | 5836 | 0.050 |
Why?
|
Graft Survival | 3 | 2009 | 3904 | 0.050 |
Why?
|
Transplantation, Homologous | 4 | 2014 | 4860 | 0.050 |
Why?
|
Antibodies, Monoclonal | 4 | 2009 | 9237 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2011 | 2324 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2014 | 3796 | 0.050 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2021 | 1441 | 0.050 |
Why?
|
Lymphatic Metastasis | 3 | 2018 | 2890 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 2 | 2011 | 3405 | 0.050 |
Why?
|
Fatigue | 2 | 2023 | 1552 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6961 | 0.050 |
Why?
|
Cohort Studies | 8 | 2022 | 41677 | 0.050 |
Why?
|
United States Department of Veterans Affairs | 1 | 2007 | 937 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2016 | 3966 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2010 | 10431 | 0.050 |
Why?
|
RNA, Neoplasm | 3 | 2010 | 744 | 0.050 |
Why?
|
Autoantibodies | 1 | 2010 | 2114 | 0.050 |
Why?
|
Transplantation, Autologous | 5 | 2007 | 2125 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 5 | 2012 | 18075 | 0.050 |
Why?
|
Signal Transduction | 4 | 2016 | 23600 | 0.050 |
Why?
|
Age Factors | 7 | 2021 | 18382 | 0.050 |
Why?
|
Pyrazines | 1 | 2007 | 1204 | 0.050 |
Why?
|
Recurrence | 6 | 2019 | 8494 | 0.050 |
Why?
|
Risk Assessment | 8 | 2017 | 24272 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2017 | 2915 | 0.050 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2002 | 249 | 0.050 |
Why?
|
Nausea | 1 | 2024 | 679 | 0.050 |
Why?
|
Waiting Lists | 1 | 2006 | 779 | 0.050 |
Why?
|
Hepatocyte Growth Factor | 2 | 2014 | 268 | 0.040 |
Why?
|
Vomiting | 1 | 2024 | 647 | 0.040 |
Why?
|
Biopsy | 3 | 2021 | 6768 | 0.040 |
Why?
|
Parathyroid Hormone | 1 | 2007 | 1790 | 0.040 |
Why?
|
Melphalan | 2 | 2007 | 425 | 0.040 |
Why?
|
Ambulatory Care | 1 | 2011 | 2778 | 0.040 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2021 | 317 | 0.040 |
Why?
|
Graft Rejection | 2 | 2011 | 4504 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2001 | 368 | 0.040 |
Why?
|
Australia | 2 | 2015 | 1260 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 6 | 2018 | 20699 | 0.040 |
Why?
|
Radiation Tolerance | 2 | 2015 | 475 | 0.040 |
Why?
|
Remission Induction | 7 | 2014 | 2413 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2020 | 404 | 0.040 |
Why?
|
Doxorubicin | 8 | 2012 | 2226 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 784 | 0.040 |
Why?
|
Animals | 17 | 2019 | 168801 | 0.040 |
Why?
|
Mice | 13 | 2019 | 81838 | 0.040 |
Why?
|
Prostatic Neoplasms | 4 | 2013 | 11092 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2011 | 2559 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 714 | 0.040 |
Why?
|
Colostomy | 1 | 2019 | 107 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2021 | 791 | 0.040 |
Why?
|
Pancreaticoduodenectomy | 2 | 2014 | 515 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 604 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2120 | 0.040 |
Why?
|
Cell Nucleus | 2 | 2020 | 2864 | 0.040 |
Why?
|
Mitomycin | 1 | 2019 | 261 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2012 | 3821 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
Patient Discharge | 1 | 2011 | 3464 | 0.040 |
Why?
|
Gastroesophageal Reflux | 1 | 2006 | 834 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6101 | 0.040 |
Why?
|
Models, Genetic | 1 | 2008 | 3448 | 0.040 |
Why?
|
Predictive Value of Tests | 6 | 2013 | 15403 | 0.040 |
Why?
|
Hearing | 1 | 2022 | 505 | 0.040 |
Why?
|
Incidence | 4 | 2019 | 21509 | 0.040 |
Why?
|
Germ-Line Mutation | 2 | 2021 | 1885 | 0.040 |
Why?
|
Busulfan | 2 | 2008 | 264 | 0.040 |
Why?
|
Sex Factors | 4 | 2016 | 10611 | 0.040 |
Why?
|
Swine, Miniature | 2 | 2010 | 972 | 0.040 |
Why?
|
Mice, Inbred BALB C | 3 | 2012 | 6215 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10380 | 0.040 |
Why?
|
Transplantation Immunology | 2 | 2010 | 540 | 0.040 |
Why?
|
Respiratory System | 1 | 2001 | 562 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2024 | 1088 | 0.040 |
Why?
|
Anilides | 1 | 2020 | 413 | 0.030 |
Why?
|
Ozone | 1 | 2001 | 499 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3664 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2006 | 2590 | 0.030 |
Why?
|
Isoantibodies | 2 | 2011 | 681 | 0.030 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 2 | 2007 | 61 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 313 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2013 | 614 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8723 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 305 | 0.030 |
Why?
|
Antilymphocyte Serum | 2 | 2010 | 492 | 0.030 |
Why?
|
Patient Selection | 3 | 2015 | 4249 | 0.030 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 615 | 0.030 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 14644 | 0.030 |
Why?
|
Leukocyte Transfusion | 2 | 2009 | 58 | 0.030 |
Why?
|
Lymphocyte Depletion | 2 | 2012 | 606 | 0.030 |
Why?
|
Anal Canal | 1 | 2019 | 376 | 0.030 |
Why?
|
Aging | 1 | 2015 | 8723 | 0.030 |
Why?
|
Gene Dosage | 2 | 2012 | 1211 | 0.030 |
Why?
|
Diethylstilbestrol | 1 | 1996 | 85 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2008 | 2532 | 0.030 |
Why?
|
Lung Transplantation | 1 | 2006 | 1310 | 0.030 |
Why?
|
Hormones | 1 | 2020 | 865 | 0.030 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3604 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 418 | 0.030 |
Why?
|
Flutamide | 1 | 1996 | 95 | 0.030 |
Why?
|
Serotonin | 1 | 2001 | 1045 | 0.030 |
Why?
|
Thoracic Wall | 1 | 2018 | 197 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2021 | 862 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2007 | 4342 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 6308 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 752 | 0.030 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 1009 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2021 | 3051 | 0.030 |
Why?
|
Faculty, Medical | 1 | 2024 | 1225 | 0.030 |
Why?
|
Surgical Procedures, Operative | 1 | 2007 | 1931 | 0.030 |
Why?
|
Case-Control Studies | 5 | 2015 | 22230 | 0.030 |
Why?
|
Esophagus | 1 | 2021 | 1039 | 0.030 |
Why?
|
Enzyme Activation | 2 | 2012 | 3584 | 0.030 |
Why?
|
Formaldehyde | 1 | 2016 | 360 | 0.030 |
Why?
|
Neoplasm Metastasis | 4 | 2018 | 4886 | 0.030 |
Why?
|
Astrocytoma | 1 | 2019 | 772 | 0.030 |
Why?
|
Alprazolam | 1 | 1995 | 103 | 0.030 |
Why?
|
Anovulation | 1 | 1995 | 56 | 0.030 |
Why?
|
Odds Ratio | 4 | 2009 | 9655 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 2010 | 4277 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2021 | 1155 | 0.030 |
Why?
|
Bleomycin | 6 | 1991 | 491 | 0.030 |
Why?
|
Radiometry | 1 | 2020 | 804 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2009 | 5791 | 0.030 |
Why?
|
Linear Energy Transfer | 1 | 2015 | 147 | 0.030 |
Why?
|
Bone Marrow Cells | 2 | 2012 | 2411 | 0.030 |
Why?
|
Family Characteristics | 1 | 2019 | 1001 | 0.030 |
Why?
|
Postoperative Complications | 3 | 2012 | 15804 | 0.030 |
Why?
|
Trimetrexate | 1 | 1994 | 15 | 0.030 |
Why?
|
Base Sequence | 3 | 2012 | 12405 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2009 | 8037 | 0.030 |
Why?
|
Liposarcoma, Myxoid | 1 | 2014 | 60 | 0.030 |
Why?
|
Histiocytoma, Malignant Fibrous | 1 | 2014 | 54 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
CA-19-9 Antigen | 1 | 2014 | 109 | 0.030 |
Why?
|
Laparoscopy | 1 | 2006 | 2039 | 0.030 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2001 | 958 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2009 | 2898 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1084 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7423 | 0.030 |
Why?
|
International Cooperation | 1 | 2019 | 1433 | 0.030 |
Why?
|
Mesna | 1 | 2012 | 62 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2013 | 6208 | 0.030 |
Why?
|
Sarcoma, Synovial | 1 | 2014 | 157 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 1 | 2014 | 336 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2018 | 4408 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7474 | 0.030 |
Why?
|
Thymidylate Synthase | 1 | 2012 | 74 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20135 | 0.030 |
Why?
|
Mastectomy, Segmental | 1 | 2018 | 965 | 0.030 |
Why?
|
Exanthema | 2 | 2007 | 503 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1592 | 0.020 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 4213 | 0.020 |
Why?
|
Luteinizing Hormone | 1 | 1995 | 828 | 0.020 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 98 | 0.020 |
Why?
|
Sacrum | 1 | 2014 | 270 | 0.020 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2013 | 307 | 0.020 |
Why?
|
Ifosfamide | 1 | 2012 | 233 | 0.020 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2012 | 86 | 0.020 |
Why?
|
Phosphorylation | 3 | 2009 | 8290 | 0.020 |
Why?
|
Supratentorial Neoplasms | 1 | 2013 | 153 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2018 | 4649 | 0.020 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2012 | 80 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 2 | 2007 | 1068 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 995 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2016 | 7118 | 0.020 |
Why?
|
Chondrosarcoma | 1 | 2014 | 301 | 0.020 |
Why?
|
Depressive Disorder, Major | 1 | 2009 | 4809 | 0.020 |
Why?
|
Codon | 1 | 2013 | 599 | 0.020 |
Why?
|
Endometrial Neoplasms | 1 | 2001 | 1379 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2014 | 6492 | 0.020 |
Why?
|
Receptors, Interferon | 1 | 2011 | 114 | 0.020 |
Why?
|
United States | 6 | 2024 | 72918 | 0.020 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 642 | 0.020 |
Why?
|
Databases, Factual | 3 | 2015 | 8062 | 0.020 |
Why?
|
Iohexol | 1 | 2012 | 205 | 0.020 |
Why?
|
Life Tables | 1 | 1991 | 366 | 0.020 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2011 | 41 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2339 | 0.020 |
Why?
|
Models, Molecular | 1 | 2021 | 5383 | 0.020 |
Why?
|
Intermediate Filament Proteins | 1 | 2011 | 261 | 0.020 |
Why?
|
Growth Disorders | 1 | 2015 | 633 | 0.020 |
Why?
|
Regression Analysis | 2 | 2012 | 6324 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2009 | 2056 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 590 | 0.020 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 1991 | 1434 | 0.020 |
Why?
|
Diarrhea | 2 | 2007 | 1315 | 0.020 |
Why?
|
Mice, Inbred C57BL | 5 | 2012 | 22339 | 0.020 |
Why?
|
Up-Regulation | 2 | 2011 | 4133 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1105 | 0.020 |
Why?
|
Inbreeding | 1 | 2009 | 48 | 0.020 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2011 | 97 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2015 | 1238 | 0.020 |
Why?
|
Reoperation | 2 | 2013 | 4308 | 0.020 |
Why?
|
Swine | 2 | 2010 | 5986 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2013 | 665 | 0.020 |
Why?
|
Hippocampus | 1 | 2022 | 3774 | 0.020 |
Why?
|
Necrosis | 1 | 2014 | 1614 | 0.020 |
Why?
|
Transfection | 2 | 2009 | 5739 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2011 | 329 | 0.020 |
Why?
|
Western World | 1 | 2009 | 26 | 0.020 |
Why?
|
Blotting, Western | 2 | 2009 | 5019 | 0.020 |
Why?
|
Mitotic Index | 1 | 2010 | 160 | 0.020 |
Why?
|
Photography | 1 | 2013 | 535 | 0.020 |
Why?
|
Radiation Injuries, Experimental | 1 | 1990 | 88 | 0.020 |
Why?
|
Dacarbazine | 1 | 2012 | 552 | 0.020 |
Why?
|
Transcription Factors | 1 | 2009 | 12128 | 0.020 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2009 | 101 | 0.020 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2009 | 83 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2007 | 9600 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2011 | 455 | 0.020 |
Why?
|
Tissue Donors | 2 | 2010 | 2389 | 0.020 |
Why?
|
Prednisolone | 1 | 2010 | 324 | 0.020 |
Why?
|
Thoracic Vertebrae | 1 | 2014 | 614 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2009 | 2454 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2011 | 656 | 0.020 |
Why?
|
Genomics | 1 | 2005 | 5924 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 977 | 0.020 |
Why?
|
Methotrexate | 6 | 1991 | 1719 | 0.020 |
Why?
|
Radiation Chimera | 1 | 2009 | 216 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2011 | 5879 | 0.020 |
Why?
|
Medical History Taking | 1 | 2012 | 779 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 683 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2017 | 1945 | 0.020 |
Why?
|
Anemia, Hemolytic | 1 | 1990 | 164 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2206 | 0.020 |
Why?
|
Probability | 2 | 1991 | 2475 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 270 | 0.020 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2009 | 411 | 0.020 |
Why?
|
Online Systems | 1 | 2009 | 181 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2530 | 0.020 |
Why?
|
Leukocytosis | 1 | 2009 | 249 | 0.020 |
Why?
|
Cell Survival | 2 | 2009 | 5744 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 3200 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2012 | 5784 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 1990 | 286 | 0.020 |
Why?
|
Reference Values | 1 | 2015 | 4909 | 0.020 |
Why?
|
Lymphopoiesis | 1 | 2009 | 132 | 0.020 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2012 | 733 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2015 | 2197 | 0.020 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2009 | 252 | 0.020 |
Why?
|
Quinazolinones | 1 | 2010 | 219 | 0.020 |
Why?
|
Dexamethasone | 6 | 1991 | 1962 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3712 | 0.020 |
Why?
|
Diaphragm | 1 | 1990 | 357 | 0.020 |
Why?
|
Therapeutic Irrigation | 1 | 2009 | 297 | 0.020 |
Why?
|
Cerebellum | 1 | 2015 | 1519 | 0.020 |
Why?
|
Cytarabine | 1 | 2010 | 696 | 0.020 |
Why?
|
Length of Stay | 2 | 2013 | 6489 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1996 | 1535 | 0.020 |
Why?
|
Self Report | 1 | 2019 | 3769 | 0.020 |
Why?
|
Cyclosporine | 1 | 2010 | 777 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2009 | 10737 | 0.020 |
Why?
|
Genes, Intracisternal A-Particle | 1 | 2007 | 4 | 0.020 |
Why?
|
Receptors, Complement 3b | 1 | 2007 | 124 | 0.020 |
Why?
|
Uric Acid | 1 | 2014 | 809 | 0.020 |
Why?
|
Macrocyclic Compounds | 1 | 2007 | 68 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2009 | 651 | 0.020 |
Why?
|
Prescriptions | 1 | 2010 | 388 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 1996 | 1411 | 0.020 |
Why?
|
Stress, Physiological | 1 | 1995 | 1404 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 904 | 0.020 |
Why?
|
Erythroblasts | 1 | 2007 | 142 | 0.020 |
Why?
|
Pyruvate Kinase | 1 | 2009 | 192 | 0.020 |
Why?
|
Visual Perception | 1 | 2016 | 1392 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3431 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3563 | 0.020 |
Why?
|
Filgrastim | 1 | 2007 | 132 | 0.020 |
Why?
|
Upper Extremity | 1 | 2012 | 684 | 0.020 |
Why?
|
Methods | 1 | 1987 | 1061 | 0.020 |
Why?
|
Hydrocortisone | 1 | 1995 | 1832 | 0.020 |
Why?
|
Air Pollutants | 1 | 2001 | 2922 | 0.020 |
Why?
|
Bone Marrow | 3 | 2011 | 2916 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2007 | 12772 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2009 | 1695 | 0.020 |
Why?
|
Penetrance | 1 | 2008 | 388 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 1729 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2010 | 1885 | 0.020 |
Why?
|
Learning | 1 | 2016 | 1755 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2008 | 870 | 0.020 |
Why?
|
Paclitaxel | 1 | 1993 | 1727 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2011 | 993 | 0.020 |
Why?
|
Drug Resistance, Multiple | 1 | 2007 | 255 | 0.020 |
Why?
|
Cell Separation | 1 | 2011 | 1718 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2718 | 0.020 |
Why?
|
Autoantigens | 1 | 2010 | 886 | 0.020 |
Why?
|
Skin Transplantation | 1 | 2011 | 1097 | 0.020 |
Why?
|
Antibody Formation | 1 | 2010 | 1392 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 3679 | 0.020 |
Why?
|
Mycophenolic Acid | 1 | 2007 | 349 | 0.020 |
Why?
|
Receptor, erbB-3 | 1 | 2006 | 141 | 0.020 |
Why?
|
Vidarabine | 1 | 2007 | 343 | 0.020 |
Why?
|
DNA Primers | 1 | 2009 | 2823 | 0.020 |
Why?
|
Attention | 1 | 2016 | 2414 | 0.020 |
Why?
|
Sample Size | 1 | 2008 | 843 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1987 | 1607 | 0.010 |
Why?
|
Cell Count | 1 | 2009 | 1825 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 12975 | 0.010 |
Why?
|
Mice, Knockout | 2 | 2011 | 14457 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2009 | 1616 | 0.010 |
Why?
|
Rats | 1 | 2001 | 23718 | 0.010 |
Why?
|
Visual Acuity | 1 | 2014 | 2672 | 0.010 |
Why?
|
Altretamine | 2 | 1996 | 11 | 0.010 |
Why?
|
Interleukin-11 | 1 | 2004 | 58 | 0.010 |
Why?
|
Lumbar Vertebrae | 1 | 2014 | 1878 | 0.010 |
Why?
|
Mastectomy | 1 | 2013 | 1848 | 0.010 |
Why?
|
Immunologic Memory | 1 | 2011 | 1377 | 0.010 |
Why?
|
Carcinoma | 1 | 1996 | 2313 | 0.010 |
Why?
|
Genetics, Population | 1 | 2009 | 943 | 0.010 |
Why?
|
Introns | 1 | 2007 | 965 | 0.010 |
Why?
|
Lower Extremity | 1 | 2012 | 1218 | 0.010 |
Why?
|
Anemia | 2 | 2009 | 1514 | 0.010 |
Why?
|
Pathology, Molecular | 1 | 2007 | 329 | 0.010 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 786 | 0.010 |
Why?
|
Epithelium | 1 | 2009 | 1604 | 0.010 |
Why?
|
Cell Death | 1 | 2009 | 1677 | 0.010 |
Why?
|
Cell Communication | 1 | 2011 | 1660 | 0.010 |
Why?
|
Bronchiolitis Obliterans | 1 | 2006 | 221 | 0.010 |
Why?
|
Quinolines | 1 | 2009 | 769 | 0.010 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 615 | 0.010 |
Why?
|
Rabbits | 1 | 2010 | 4730 | 0.010 |
Why?
|
Protozoan Infections | 1 | 2003 | 39 | 0.010 |
Why?
|
Imidazoles | 1 | 2009 | 1169 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2006 | 895 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1362 | 0.010 |
Why?
|
Acute Disease | 1 | 2014 | 7237 | 0.010 |
Why?
|
Leukopenia | 2 | 1994 | 213 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2011 | 1600 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3801 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2014 | 5503 | 0.010 |
Why?
|
Employment | 1 | 2009 | 1108 | 0.010 |
Why?
|
Hot Temperature | 1 | 2009 | 1440 | 0.010 |
Why?
|
Osteosarcoma | 1 | 2008 | 908 | 0.010 |
Why?
|
Mammaplasty | 1 | 2013 | 1264 | 0.010 |
Why?
|
Mice, Nude | 1 | 2009 | 3610 | 0.010 |
Why?
|
Social Behavior | 1 | 2009 | 1143 | 0.010 |
Why?
|
Administration, Oral | 2 | 2004 | 4016 | 0.010 |
Why?
|
Protein Kinases | 1 | 2009 | 1610 | 0.010 |
Why?
|
Sirolimus | 1 | 2009 | 1541 | 0.010 |
Why?
|
Homozygote | 1 | 2007 | 1774 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2007 | 1331 | 0.010 |
Why?
|
Fetal Blood | 1 | 2009 | 1365 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2006 | 1494 | 0.010 |
Why?
|
Platelet Count | 1 | 2004 | 784 | 0.010 |
Why?
|
Logistic Models | 2 | 2012 | 13272 | 0.010 |
Why?
|
Megestrol | 1 | 2001 | 9 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2006 | 1613 | 0.010 |
Why?
|
Aspergillosis | 1 | 2003 | 242 | 0.010 |
Why?
|
Epidermal Growth Factor | 1 | 2004 | 697 | 0.010 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2003 | 239 | 0.010 |
Why?
|
Point Mutation | 1 | 2006 | 1591 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2006 | 1691 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2010 | 2156 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 26280 | 0.010 |
Why?
|
Phosphoproteins | 1 | 2009 | 2445 | 0.010 |
Why?
|
Exercise Tolerance | 1 | 2006 | 841 | 0.010 |
Why?
|
Genetic Testing | 1 | 2014 | 3592 | 0.010 |
Why?
|
Parents | 1 | 2014 | 3591 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6057 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2004 | 1605 | 0.010 |
Why?
|
Exons | 1 | 2006 | 2392 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2009 | 2419 | 0.010 |
Why?
|
Erythropoietin | 1 | 2004 | 716 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2009 | 18321 | 0.010 |
Why?
|
Cell Movement | 1 | 2011 | 5194 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 2879 | 0.010 |
Why?
|
Health Surveys | 1 | 2009 | 4054 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4779 | 0.010 |
Why?
|
Kidney Diseases | 1 | 1990 | 2100 | 0.010 |
Why?
|
Cell Cycle | 1 | 2007 | 2921 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2009 | 2593 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2011 | 4399 | 0.010 |
Why?
|
Contrast Media | 1 | 2012 | 5330 | 0.010 |
Why?
|
NF-kappa B | 1 | 2007 | 2495 | 0.010 |
Why?
|
Blood Platelets | 1 | 2009 | 2464 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2009 | 3436 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 3499 | 0.010 |
Why?
|
Thymus Gland | 1 | 2003 | 1259 | 0.010 |
Why?
|
Massachusetts | 1 | 2011 | 8882 | 0.010 |
Why?
|
RNA Interference | 1 | 2006 | 2825 | 0.010 |
Why?
|
HLA Antigens | 1 | 2003 | 1338 | 0.010 |
Why?
|
DNA Methylation | 1 | 2012 | 4426 | 0.010 |
Why?
|
DNA Repair | 1 | 2007 | 2048 | 0.010 |
Why?
|
Surgical Wound Infection | 1 | 2007 | 1543 | 0.010 |
Why?
|
RNA | 1 | 2007 | 2715 | 0.010 |
Why?
|
Virus Diseases | 1 | 2003 | 720 | 0.010 |
Why?
|
Kidney | 2 | 2009 | 7072 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2003 | 1789 | 0.010 |
Why?
|
Tamoxifen | 1 | 2001 | 964 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15820 | 0.010 |
Why?
|
Neutrophils | 1 | 2009 | 3770 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2016 | 36547 | 0.010 |
Why?
|
Chronic Disease | 1 | 2010 | 9351 | 0.010 |
Why?
|
Stroke | 1 | 2017 | 9743 | 0.010 |
Why?
|
Computer Simulation | 1 | 2008 | 6254 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 10577 | 0.010 |
Why?
|
Phenotype | 1 | 2012 | 16714 | 0.010 |
Why?
|
Models, Biological | 1 | 2010 | 9446 | 0.010 |
Why?
|
Obesity | 1 | 2015 | 13082 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2007 | 7599 | 0.010 |
Why?
|
Receptors, GABA | 1 | 1995 | 312 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2013 | 26379 | 0.010 |
Why?
|
Hemorrhage | 1 | 2004 | 3464 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2010 | 11642 | 0.010 |
Why?
|
Pyridoxine | 1 | 1992 | 108 | 0.010 |
Why?
|
Health Status | 1 | 2004 | 4083 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 3246 | 0.010 |
Why?
|
Erythrocyte Aging | 1 | 1990 | 51 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1990 | 370 | 0.010 |
Why?
|
Thromboembolism | 1 | 1996 | 1001 | 0.010 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 1990 | 105 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1996 | 2108 | 0.010 |
Why?
|
Splenomegaly | 1 | 1990 | 191 | 0.010 |
Why?
|
Lymphography | 1 | 1990 | 189 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2007 | 5189 | 0.000 |
Why?
|
Hair Color | 1 | 1989 | 131 | 0.000 |
Why?
|
Mice, Inbred C3H | 1 | 1990 | 915 | 0.000 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 1993 | 1142 | 0.000 |
Why?
|
Drug Resistance | 1 | 1993 | 1592 | 0.000 |
Why?
|
Kidney Glomerulus | 1 | 1990 | 567 | 0.000 |
Why?
|
Laparotomy | 1 | 1990 | 459 | 0.000 |
Why?
|
Hemolysis | 1 | 1989 | 408 | 0.000 |
Why?
|
Estrogens | 1 | 1993 | 1528 | 0.000 |
Why?
|
Prednisone | 1 | 1991 | 1566 | 0.000 |
Why?
|
Erythropoiesis | 1 | 1990 | 691 | 0.000 |
Why?
|
Thrombocytopenia | 1 | 1994 | 1172 | 0.000 |
Why?
|
Random Allocation | 1 | 1990 | 2395 | 0.000 |
Why?
|
Central Nervous System Diseases | 1 | 1990 | 519 | 0.000 |
Why?
|
Death, Sudden, Cardiac | 1 | 1993 | 1566 | 0.000 |
Why?
|
Cataract | 1 | 1989 | 837 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1996 | 12426 | 0.000 |
Why?
|
Hematopoiesis | 1 | 1989 | 2060 | 0.000 |
Why?
|
Calcium | 1 | 1991 | 5770 | 0.000 |
Why?
|
Weight Loss | 1 | 1989 | 2711 | 0.000 |
Why?
|
Myocardial Infarction | 1 | 1993 | 11506 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1996 | 15639 | 0.000 |
Why?
|